Search Results - "Elassaiss‐Schaap, J"

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors by Ahamadi, M, Freshwater, T, Prohn, M, Li, CH, de Alwis, DP, de Greef, R, Elassaiss‐Schaap, J, Kondic, A, Stone, JA

“…Pembrolizumab, a potent antibody against programmed death 1 (PD‐1) receptor, has shown robust antitumor activity and manageable safety in patients with…”
Get full text

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab by Lindauer, A, Valiathan, CR, Mehta, K, Sriram, V, de Greef, R, Elassaiss‐Schaap, J, de Alwis, DP

“…Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1), has a manageable safety profile and robust clinical activity against advanced…”
Get full text

Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial by Elassaiss‐Schaap, J, Rossenu, S, Lindauer, A, Kang, SP, de Greef, R, Sachs, JR, de Alwis, DP

“…Evaluation of pharmacokinetic/pharmacodynamic (PK/PD) properties played an important role in the early clinical development of pembrolizumab. Because analysis…”
Get full text

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma by Chatterjee, MS, Elassaiss‐Schaap, J, Lindauer, A, Turner, DC, Sostelly, A, Freshwater, T, Mayawala, K, Ahamadi, M, Stone, JA, Greef, R, Kondic, AG, Alwis, DP

“…Pembrolizumab is a potent immune‐modulating antibody active in advanced melanoma, as demonstrated in the KEYNOTE‐001, ‐002, and ‐006 studies. Longitudinal…”
Get full text

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma by de Greef, R, Elassaiss‐Schaap, J, Chatterjee, M, Turner, DC, Ahamadi, M, Forman, M, Cutler, D, de Alwis, DP, Kondic, A, Stone, J

“…Recently, immunotherapy has yielded promising results in several cancer types. Contrary to the established classical chemotherapy‐dosing paradigm, a maximum…”
Get full text

Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats by van den Brink, W.J., Elassaiss-Schaap, J., Gonzalez-Amoros, B., Harms, A.C., van der Graaf, P.H., Hankemeier, T., de Lange, E.C.M.

“…The study of central nervous system (CNS) pharmacology is limited by a lack of drug effect biomarkers. Pharmacometabolomics is a promising new tool to identify…”
Get full text

3344 Relationship between pembrolizumab exposure and efficacy/safety in 1016 patients (pts) with advanced or metastatic melanoma by Kang, S.P, Chatterjee, M, Ahamadi, M, De Alwis, D, De Greef, R, Elassaiss-Schaap, J, Freshwater, T, Mayawala, K, Stone, J, Ebbinghaus, S, Turner, D, Kondic, A

Get full text

Desmopressin as a pharmacological tool in vasopressinergic hypothalamus–pituitary–adrenal axis modulation: neuroendocrine, cardiovascular and coagulatory effects by Jacobs, GE, Hulskotte, EGJ, van Gerven, JMA, Zuurman, L, de Kam, ML, Elassaiss-Schaap, J, Ruigt, G, van Pelt, J, Peeters, BWMM, Peeters, PAM, Burggraaf, J

“…Arginine-vasopressin (AVP) is a physiological co-activator of the hypothalamus–pituitary–adrenal (HPA) axis, together with corticotrophin releasing hormone…”
Get full text

A pharmacological tool to assess vasopressinergic co-activation of the hypothalamus–pituitary–adrenal axis more integrally in healthy volunteers by Jacobs, GE, van Gerven, JMA, de Kam, ML, Elassaiss-Schaap, J, Ruigt, G, van Pelt, J, Peeters, BWMM, Peeters, PAM, Hulskotte, EGJ

“…Pharmacological function tests consisting of 100 µg hCRH (corticorelin) and 10 µg dDAVP (desmopressin) mimic endogenous hypothalamus–pituitary–adrenal (HPA)…”
Get full text

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors: Pharmacokinetics of Pembro in Solid Tumors by Ahamadi, M, Freshwater, T, Prohn, M, Li, CH, de Alwis, DP, de Greef, R, Elassaiss-Schaap, J, Kondic, A, Stone, JA

Get full text

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab: Translational Pharmacokinetic/Pharmacodynamic Modeling by Lindauer, A, Valiathan, CR, Mehta, K, Sriram, V, de Greef, R, Elassaiss-Schaap, J, de Alwis, DP

Get full text

Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial: Modeling of the PK/PD of Pembro in KEYNOTE-001 by Elassaiss-Schaap, J, Rossenu, S, Lindauer, A, Kang, SP, de Greef, R, Sachs, JR, de Alwis, DP

Get full text

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma: Modeling and Simulation of Pembrolizumab by de Greef, R, Elassaiss-Schaap, J, Chatterjee, M, Turner, DC, Ahamadi, M, Forman, M, Cutler, D, de Alwis, DP, Kondic, A, Stone, J

Get full text

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma: Tumor Modeling in Pembrolizumab-Treated Melanoma by Chatterjee, MS, Elassaiss-Schaap, J, Lindauer, A, Turner, DC, Sostelly, A, Freshwater, T, Mayawala, K, Ahamadi, M, Stone, JA, de Greef, R, Kondic, AG, de Alwis, DP

Get full text